Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:3:p8
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 3 (pt 8/8)
Character Range: 178949–180749

containing 40% or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10% or less of sulfacetamide.
SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.
TERBUTALINE as the only therapeutically active substance:
 (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
 (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.
THEOPHYLLINE in liquid oral preparations containing 2% or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1% or less of triamcinolone in a pack of 5 g or less.
TRIPROLIDINE in oral preparations except:
 (a) when included in Schedule 2; or
 (b) for the treatment of children under 2 years of age.
ULIPRISTAL for emergency post‑coital contraception.
VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.
ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of symptoms.